{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:06:46Z","timestamp":1790096806231,"version":"4.0.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,11,15]],"date-time":"2011-11-15T00:00:00Z","timestamp":1321315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2011,11,15]],"date-time":"2011-11-15T00:00:00Z","timestamp":1321315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1038\/tpj.2011.48","type":"journal-article","created":{"date-parts":[[2011,11,15]],"date-time":"2011-11-15T13:23:46Z","timestamp":1321363426000},"page":"94-104","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["A genomic approach to predict synergistic combinations for breast cancer treatment"],"prefix":"10.1038","volume":"13","author":[{"given":"R","family":"Soldi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A L","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P J","family":"Moos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A H","family":"Bild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,11,15]]},"reference":[{"key":"BFtpj201148_CR1","volume-title":"SEER Cancer Statistics Review 1975\u20132007","author":"S Altekruse","year":"2010","unstructured":"Altekruse S, Kosary C, Krapcho M, Neyman N, Aminou R, Waldron W et al. SEER Cancer Statistics Review 1975\u20132007. National Cancer Institute: Bethesda, MD. http:\/\/seer.cancer.gov\/csr\/1975_2007\/, Access based on November 2009 SEER data submission, posted to the SEER website, 2010."},{"key":"BFtpj201148_CR2","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1056\/NEJMp1101548","volume":"364","author":"J Woodcock","year":"2011","unstructured":"Woodcock J, Griffin JP, Behrman RE . Development of novel combination therapies. N Engl J Med 2011; 364: 985\u2013987.","journal-title":"N Engl J Med"},{"key":"BFtpj201148_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","volume":"100","author":"D Hanahan","year":"2000","unstructured":"Hanahan D, Weinberg RA . The hallmarks of cancer. Cell 2000; 100: 57\u201370.","journal-title":"Cell"},{"key":"BFtpj201148_CR4","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1101\/gad.1232504","volume":"18","author":"AH Lund","year":"2004","unstructured":"Lund AH, van Lohuizen M . Epigenetics and cancer. Genes Dev 2004; 18: 2315\u20132335.","journal-title":"Genes Dev"},{"key":"BFtpj201148_CR5","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nrc1799","volume":"6","author":"SB Baylin","year":"2006","unstructured":"Baylin SB, Ohm JE . Epigenetic gene silencing in cancer\u2014a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006; 6: 107\u2013116.","journal-title":"Nat Rev Cancer"},{"key":"BFtpj201148_CR6","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1146\/annurev.biochem.70.1.81","volume":"70","author":"SY Roth","year":"2001","unstructured":"Roth SY, Denu JM, Allis CD . Histone acetyltransferases. Annu Rev Biochem 2001; 70: 81\u2013120.","journal-title":"Annu Rev Biochem"},{"key":"BFtpj201148_CR7","doi-asserted-by":"publisher","first-page":"549","DOI":"10.4161\/cc.4.4.1564","volume":"4","author":"PA Marks","year":"2005","unstructured":"Marks PA, Jiang X . Histone deacetylase inhibitors in programmed cell death and cancer therapy. Cell Cycle 2005; 4: 549\u2013551.","journal-title":"Cell Cycle"},{"key":"BFtpj201148_CR8","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/nrd2133","volume":"5","author":"JE Bolden","year":"2006","unstructured":"Bolden JE, Peart MJ, Johnstone RW . Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5: 769\u2013784.","journal-title":"Nat Rev Drug Discov"},{"key":"BFtpj201148_CR9","doi-asserted-by":"publisher","first-page":"6962","DOI":"10.1158\/1078-0432.CCR-04-0455","volume":"10","author":"Z Zhang","year":"2004","unstructured":"Zhang Z, Yamashita H, Toyama T, Sugiura H, Omoto Y, Ando Y et al. HDAC6 expression is correlated with better survival in breast cancer. Clin Cancer Res 2004; 10: 6962\u20136968.","journal-title":"Clin Cancer Res"},{"key":"BFtpj201148_CR10","doi-asserted-by":"publisher","first-page":"13548","DOI":"10.1074\/jbc.M510023200","volume":"281","author":"AJ Wilson","year":"2006","unstructured":"Wilson AJ, Byun DS, Popova N, Murray LB, L\u2032Italien K, Sowa Y et al. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem 2006; 281: 13548\u201313558.","journal-title":"J Biol Chem"},{"key":"BFtpj201148_CR11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s10549-005-6001-1","volume":"94","author":"Z Zhang","year":"2005","unstructured":"Zhang Z, Yamashita H, Toyama T, Sugiura H, Ando Y, Mita K et al. Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*. Breast Cancer Res Treat 2005; 94: 11\u201316.","journal-title":"Breast Cancer Res Treat"},{"key":"BFtpj201148_CR12","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/pros.20022","volume":"59","author":"K Halkidou","year":"2004","unstructured":"Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE, Robson CN . Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 2004; 59: 177\u2013189.","journal-title":"Prostate"},{"key":"BFtpj201148_CR13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.canlet.2008.03.037","volume":"269","author":"JS Carew","year":"2008","unstructured":"Carew JS, Giles FJ, Nawrocki ST . Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett 2008; 269: 7\u201317.","journal-title":"Cancer Lett"},{"key":"BFtpj201148_CR14","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/0470862637.ch20","volume":"259","author":"PA Marks","year":"2004","unstructured":"Marks PA, Richon VM, Kelly WK, Chiao JH, Miller T . Histone deacetylase inhibitors: development as cancer therapy. Novartis Foundation Symposium 2004; 259: 269\u2013281;, discussion 281-268.","journal-title":"Novartis Foundation Symposium"},{"key":"BFtpj201148_CR15","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1517\/13543784.11.12.1695","volume":"11","author":"WK Kelly","year":"2002","unstructured":"Kelly WK, O\u2032Connor OA, Marks PA . Histone deacetylase inhibitors: from target to clinical trials. Expert Opin Investig Drugs 2002; 11: 1695\u20131713.","journal-title":"Expert Opin Investig Drugs"},{"key":"BFtpj201148_CR16","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1158\/1078-0432.CCR-03-0100","volume":"10","author":"N Takai","year":"2004","unstructured":"Takai N, Desmond JC, Kumagai T, Gui D, Said JW, Whittaker S et al. Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clin Cancer Res 2004; 10: 1141\u20131149.","journal-title":"Clin Cancer Res"},{"key":"BFtpj201148_CR17","doi-asserted-by":"publisher","first-page":"4389","DOI":"10.1073\/pnas.0430973100","volume":"100","author":"SJ Haggarty","year":"2003","unstructured":"Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL . Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci USA 2003; 100: 4389\u20134394.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFtpj201148_CR18","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1093\/carcin\/bgn010","volume":"29","author":"V Cucciolla","year":"2008","unstructured":"Cucciolla V, Borriello A, Criscuolo M, Sinisi AA, Bencivenga D, Tramontano A et al. Histone deacetylase inhibitors upregulate p57Kip2 level by enhancing its expression through Sp1 transcription factor. Carcinogenesis 2008; 29: 560\u2013567.","journal-title":"Carcinogenesis"},{"key":"BFtpj201148_CR19","doi-asserted-by":"publisher","first-page":"10220","DOI":"10.1128\/MCB.25.23.10220-10234.2005","volume":"25","author":"F Faiola","year":"2005","unstructured":"Faiola F, Liu X, Lo S, Pan S, Zhang K, Lymar E et al. Dual regulation of c-Myc by p300 via acetylation-dependent control of Myc protein turnover and coactivation of Myc-induced transcription. Mol Cell Biol 2005; 25: 10220\u201310234.","journal-title":"Mol Cell Biol"},{"key":"BFtpj201148_CR20","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1097\/CAD.0b013e32832e14e1","volume":"20","author":"A Monks","year":"2009","unstructured":"Monks A, Hose CD, Pezzoli P, Kondapaka S, Vansant G, Petersen KD et al. Gene expression-signature of belinostat in cell lines is specific for histone deacetylase inhibitor treatment, with a corresponding signature in xenografts. Anticancer Drugs 2009; 20: 682\u2013692.","journal-title":"Anticancer Drugs"},{"key":"BFtpj201148_CR21","first-page":"151","volume":"2","author":"KB Glaser","year":"2003","unstructured":"Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG, Davidsen SK . Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2003; 2: 151\u2013163.","journal-title":"Mol Cancer Ther"},{"key":"BFtpj201148_CR22","doi-asserted-by":"publisher","first-page":"e5011","DOI":"10.1371\/journal.pone.0005011","volume":"4","author":"X Yang","year":"2009","unstructured":"Yang X, Karuturi RK, Sun F, Aau M, Yu K, Shao R et al. CDKN1C (p57) is a direct target of EZH2 and suppressed by multiple epigenetic mechanisms in breast cancer cells. PLoS One 2009; 4: e5011.","journal-title":"PLoS One"},{"key":"BFtpj201148_CR23","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1038\/sj.onc.1205376","volume":"21","author":"T Kikuchi","year":"2002","unstructured":"Kikuchi T, Toyota M, Itoh F, Suzuki H, Obata T, Yamamoto H et al. Inactivation of p57KIP2 by regional promoter hypermethylation and histone deacetylation in human tumors. Oncogene 2002; 21: 2741\u20132749.","journal-title":"Oncogene"},{"key":"BFtpj201148_CR24","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1002\/ijc.22214","volume":"119","author":"IS Pateras","year":"2006","unstructured":"Pateras IS, Apostolopoulou K, Koutsami M, Evangelou K, Tsantoulis P, Liloglou T et al. Downregulation of the KIP family members p27(KIP1) and p57(KIP2) by SKP2 and the role of methylation in p57(KIP2) inactivation in nonsmall cell lung cancer. Int J Cancer 2006; 119: 2546\u20132556.","journal-title":"Int J Cancer"},{"key":"BFtpj201148_CR25","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1476-4598-5-44","volume":"5","author":"J Hayslip","year":"2006","unstructured":"Hayslip J, Montero A . Tumor suppressor gene methylation in follicular lymphoma: a comprehensive review. Mol Cancer 2006; 5: 44.","journal-title":"Mol Cancer"},{"key":"BFtpj201148_CR26","doi-asserted-by":"publisher","first-page":"e4482","DOI":"10.1371\/journal.pone.0004482","volume":"4","author":"EM Algar","year":"2009","unstructured":"Algar EM, Muscat A, Dagar V, Rickert C, Chow CW, Biegel JA et al. Imprinted CDKN1C is a tumor suppressor in rhabdoid tumor and activated by restoration of SMARCB1 and histone deacetylase inhibitors. PLoS One 2009; 4: e4482.","journal-title":"PLoS One"},{"key":"BFtpj201148_CR27","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/1471-2407-8-68","volume":"8","author":"PS Larson","year":"2008","unstructured":"Larson PS, Schlechter BL, King CL, Yang Q, Glass CN, Mack C et al. CDKN1C\/p57kip2 is a candidate tumor suppressor gene in human breast cancer. BMC Cancer 2008; 8: 68.","journal-title":"BMC Cancer"},{"key":"BFtpj201148_CR28","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S0022-3565(24)29450-7","volume":"298","author":"RJ Tallarida","year":"2001","unstructured":"Tallarida RJ . Drug synergism: its detection and applications. J Pharmacol Exp Ther 2001; 298: 865\u2013872.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFtpj201148_CR29","doi-asserted-by":"publisher","first-page":"14621","DOI":"10.1073\/pnas.1000138107","volume":"107","author":"F Iorio","year":"2010","unstructured":"Iorio F, Bosotti R, Scacheri E, Belcastro V, Mithbaokar P, Ferriero R et al. Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc Natl Acad Sci USA 2010; 107: 14621\u201314626.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFtpj201148_CR30","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1158\/1535-7163.MCT-09-0083","volume":"8","author":"W Berkofsky-Fessler","year":"2009","unstructured":"Berkofsky-Fessler W, Nguyen TQ, Delmar P, Molnos J, Kanwal C, DePinto W et al. Preclinical biomarkers for a cyclin-dependent kinase inhibitor translate to candidate pharmacodynamic biomarkers in phase I patients. Mol Cancer Ther 2009; 8: 2517\u20132525.","journal-title":"Mol Cancer Ther"},{"key":"BFtpj201148_CR31","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1126\/science.1132939","volume":"313","author":"J Lamb","year":"2006","unstructured":"Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006; 313: 1929\u20131935.","journal-title":"Science"},{"key":"BFtpj201148_CR32","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1158\/0008-5472.CAN-08-2216","volume":"69","author":"DS Welsbie","year":"2009","unstructured":"Welsbie DS, Xu J, Chen Y, Borsu L, Scher HI, Rosen N et al. Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer Res 2009; 69: 958\u2013966.","journal-title":"Cancer Res"},{"key":"BFtpj201148_CR33","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1152\/physiolgenomics.00193.2004","volume":"20","author":"JR Wood","year":"2005","unstructured":"Wood JR, Nelson-Degrave VL, Jansen E, McAllister JM, Mosselman S, Strauss III JF . Valproate-induced alterations in human theca cell gene expression: clues to the association between valproate use and metabolic side effects. Physiol Genomics 2005; 20: 233\u2013243.","journal-title":"Physiol Genomics"},{"key":"BFtpj201148_CR34","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/j.1432-1033.1997.t01-2-00527.x","volume":"243","author":"L Meijer","year":"1997","unstructured":"Meijer L, Borgne A, Mulner O, Chong JP, Blow JJ, Inagaki N et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 1997; 243: 527\u2013536.","journal-title":"Eur J Biochem"},{"key":"BFtpj201148_CR35","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1158\/1535-7163.1427.3.11","volume":"3","author":"DW Fry","year":"2004","unstructured":"Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E et al. Specific inhibition of cyclin-dependent kinase 4\/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 2004; 3: 1427\u20131438.","journal-title":"Mol Cancer Ther"},{"key":"BFtpj201148_CR36","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.ccr.2006.10.008","volume":"10","author":"RM Neve","year":"2006","unstructured":"Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006; 10: 515\u2013527.","journal-title":"Cancer Cell"},{"key":"BFtpj201148_CR37","first-page":"17","volume":"7","author":"MJ Bissell","year":"2005","unstructured":"Bissell MJ, Labarge MA . Context, tissue plasticity, and cancer: are tumor stem cells also regulated by the microenvironment? Cancer Cell 2005; 7: 17\u201323.","journal-title":"Cancer Cell"},{"key":"BFtpj201148_CR38","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/nrm1858","volume":"7","author":"LG Griffith","year":"2006","unstructured":"Griffith LG, Swartz MA . Capturing complex 3D tissue physiology in vitro. Nat Rev Mol Cell Biol 2006; 7: 211\u2013224.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"BFtpj201148_CR39","unstructured":"American Cancer Society. Cancer Facts & Figures. American Cancer Society: Atlanta, 2011."},{"key":"BFtpj201148_CR40","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1093\/annonc\/mdn739","volume":"20","author":"AU Buzdar","year":"2009","unstructured":"Buzdar AU . Role of biologic therapy and chemotherapy in hormone receptor- and HER2-positive breast cancer. Ann Oncol 2009; 20: 993\u2013999.","journal-title":"Ann Oncol"},{"key":"BFtpj201148_CR41","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1158\/1078-0432.CCR-08-1930","volume":"15","author":"P Munster","year":"2009","unstructured":"Munster P, Marchion D, Bicaku E, Lacevic M, Kim J, Centeno B et al. Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I\/II trial of valproic acid and epirubicin\/FEC. Clin Cancer Res 2009; 15: 2488\u20132496.","journal-title":"Clin Cancer Res"},{"key":"BFtpj201148_CR42","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.biocel.2008.08.019","volume":"41","author":"L Travaglini","year":"2009","unstructured":"Travaglini L, Vian L, Billi M, Grignani F, Nervi C . Epigenetic reprogramming of breast cancer cells by valproic acid occurs regardless of estrogen receptor status. Int J Biochem Cell Biol 2009; 41: 225\u2013234.","journal-title":"Int J Biochem Cell Biol"},{"key":"BFtpj201148_CR43","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1475-2867-6-2","volume":"6","author":"A Chavez-Blanco","year":"2006","unstructured":"Chavez-Blanco A, Perez-Plasencia C, Perez-Cardenas E, Carrasco-Legleu C, Rangel-Lopez E, Segura-Pacheco B et al. Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines. Cancer Cell Int 2006; 6: 2.","journal-title":"Cancer Cell Int"},{"key":"BFtpj201148_CR44","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1093\/annonc\/mdm204","volume":"18","author":"M Candelaria","year":"2007","unstructured":"Candelaria M, Gallardo-Rincon D, Arce C, Cetina L, Aguilar-Ponce JL, Arrieta O et al. A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Ann Oncol 2007; 18: 1529\u20131538.","journal-title":"Ann Oncol"},{"key":"BFtpj201148_CR45","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1200\/JCO.2006.08.6165","volume":"25","author":"P Munster","year":"2007","unstructured":"Munster P, Marchion D, Bicaku E, Schmitt M, Lee JH, DeConti R et al. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol 2007; 25: 1979\u20131985.","journal-title":"J Clin Oncol"},{"key":"BFtpj201148_CR46","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1371\/journal.pone.0000098","volume":"1","author":"C Arce","year":"2006","unstructured":"Arce C, Perez-Plasencia C, Gonzalez-Fierro A, de la Cruz-Hernandez E, Revilla-Vazquez A, Chavez-Blanco A et al. A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer. PLoS One 2006; 1: e98.","journal-title":"PLoS One"},{"key":"BFtpj201148_CR47","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/35021093","volume":"406","author":"CM Perou","year":"2000","unstructured":"Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747\u2013752.","journal-title":"Nature"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/tpj201148.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tpj201148","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tpj201148.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T02:50:52Z","timestamp":1741920652000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/tpj201148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,15]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["BFtpj201148"],"URL":"https:\/\/doi.org\/10.1038\/tpj.2011.48","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,15]]},"assertion":[{"value":"5 April 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2011","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2011","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2011","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}